Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sinovac Biotech : Some parts of China battle tight supply of COVID-19 vaccines -state media

04/21/2021 | 04:39am EDT

BEIJING, April 21 (Reuters) - Residents of some parts of China that are grappling with tight supplies of coronavirus vaccines have not received their second doses in time, but the crunch will ease by June as production is being stepped up, a health official told state media.

The pace of China's massive inoculation campaign has slowed, to a daily average of about 3.3 million doses in the seven days until Monday, down from the corresponding figure of 4.2 million in the week until April 12, Reuters calculations showed.

"At present, domestic vaccine supply is relatively tight, but from May, especially after June, the situation will ease significantly," Zheng Zhongwei, the director of a team coordinating vaccine development projects, told the Global Times in an interview.

Zheng did not say how severe the crunch was or which areas experienced tightness. The Global Times, published by the official newspaper of the ruling Communist Party, did not say how long people in those areas had to wait for the second shot.

By Wednesday, China had given more than 200 million doses of vaccines, ranking only behind the United States, and it aims to inoculate 40% of its population by summer.

Big cities such as Beijing and Shanghai have widened vaccination efforts to include foreigners, with the pace in some cities outstripping the national average, as China prioritises supplies to key provinces.

The capital city of Beijing, for example, has inoculated more than half of its population of 21.5 million.

This month Zheng said China was likely to have produced 3 billion doses of the vaccines by year-end, allowing it to meet the demand in the second half of 2021.

China's national guidelines allow intervals of up to eight weeks between the two doses of vaccines developed by domestic firms Sinopharm and Sinovac Biotech.

Local authorities should make sure the second dose can be administered within eight weeks, said Mi Feng, a spokesman of the National Health Commission.

"Avoid the situation where there's no dose following the first one," he told a news conference on Wednesday.

(Global vaccination tracker: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access/)

(Reporting by Roxanne Liu and Ryan Woo; Editing by Michael Perry and Clarence Fernandez)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
SINOPHARM GROUP CO., LTD. -0.38% 26 End-of-day quote.37.86%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.0.00%
All news about SINOVAC BIOTECH LTD.
06/09China to study using CanSinoBIO COVID shots as a booster
RE
06/08SINOVAC BIOTECHá : Pfizer/BioNtech COVID-19 vaccines prove highly effective in U..
RE
06/07ASTRAZENECAá : Thailand starts long awaited COVID-19 vaccination drive
RE
06/04SINOVAC BIOTECHá : WHO warns of 'failure' unless rich countries speed up vaccine..
RE
06/04SINOVAC BIOTECHá : WHO urges countries to follow U.S., give vaccine doses to fil..
RE
06/02ASTRAZENECAá : commits to 1.8 million Thai vaccine doses amid supply anxiety
RE
06/02SINOVAC BIOTECHá : COVID-19 Vaccine Wins World Health Organization Approval for ..
MT
06/02SINOVAC BIOTECHá : World Health Organization Authorizes SINOVAC's CoronaVac« for..
BU
06/02MARKET CHATTER : GAVI in Talks With Sinovac Biotech to Expand COVID-19 Vaccine S..
MT
06/02SINOVAC BIOTECHá : GAVI in talks with China's Sinovax to expand COVAX supply - s..
RE
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 110 M - -
Net cash 2020 1 040 M - -
P/E ratio 2020 6,66x
Yield 2020 -
Capitalization 642 M 642 M -
EV / Sales 2019 1,86x
EV / Sales 2020 -0,78x
Nbr of Employees 1 959
Free-Float 33,1%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang CFO & Vice President-Business Development
Qiang Gao Chief Operating Officer & Vice President
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SINOVAC BIOTECH LTD.0.00%642
CSL LIMITED4.75%103 884
WUXI BIOLOGICS (CAYMAN) INC.21.40%67 880
BIOGEN INC.61.99%59 716
SAMSUNG BIOLOGICS CO.,LTD.3.27%50 040
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.30.69%48 336